These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 3134119

  • 1. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
    Doberauer C, Niederle N, Schmidt CG.
    Cancer; 1988 Aug 01; 62(3):474-8. PubMed ID: 3134119
    [Abstract] [Full Text] [Related]

  • 2. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.
    Falkson CI, Falkson HC, Falkson G.
    Eur J Cancer; 1991 Aug 01; 27(10):1208-11. PubMed ID: 1835587
    [Abstract] [Full Text] [Related]

  • 3. Combination treatment in M1 prostate cancer.
    Ferrari P, Castagnetti G, Ferrari G, Pollastri CA, Tavoni F, Dotti A.
    Cancer; 1993 Dec 15; 72(12 Suppl):3880-5. PubMed ID: 8252509
    [Abstract] [Full Text] [Related]

  • 4. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer.
    Walker KJ, Walker RF, Turkes A, Robertson JF, Blamey RW, Griffiths K, Nicholson RI.
    Eur J Cancer Clin Oncol; 1989 Apr 15; 25(4):651-4. PubMed ID: 2523808
    [Abstract] [Full Text] [Related]

  • 5. Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer.
    Lissoni P, Barni S, Crispino S, Cattaneo G, Tancini G.
    Tumori; 1988 Jun 30; 74(3):303-8. PubMed ID: 2840764
    [Abstract] [Full Text] [Related]

  • 6. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI, Walker KJ.
    Chemioterapia; 1985 Jun 30; 4(3):249-51. PubMed ID: 3161643
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer.
    Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S.
    Cancer; 1993 Jul 15; 72(2):502-5. PubMed ID: 8319180
    [Abstract] [Full Text] [Related]

  • 9. [Buserelin therapy in postmenopausal patients with advanced breast carcinoma].
    Vici P, Veltri E, Carpano S, Di Lauro L, Lopez M.
    Clin Ter; 1991 Feb 15; 136(3):195-9. PubMed ID: 1827382
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.
    Klijn JG, de Jong FH, Blankenstein MA, Docter R, Alexieva-Figusch J, Blonk-van der Wijst J, Lamberts SW.
    Breast Cancer Res Treat; 1984 Feb 15; 4(3):209-20. PubMed ID: 6435703
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C, Denis L.
    Am J Clin Oncol; 1988 Feb 15; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [Abstract] [Full Text] [Related]

  • 12. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R, Lachance R, Dupont A, Labrie F.
    J Clin Endocrinol Metab; 1986 Aug 15; 63(2):297-302. PubMed ID: 3522618
    [Abstract] [Full Text] [Related]

  • 13. Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
    Ferrari V, Zaniboni A, Simoncini E, Marpicati E, Montini E, Moretti R, Marini G.
    Chemioterapia; 1988 Dec 15; 7(6):414-9. PubMed ID: 3146444
    [Abstract] [Full Text] [Related]

  • 14. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI, Falkson G, Falkson HC.
    Ann Oncol; 1991 Apr 15; 2(4):303-4. PubMed ID: 1907843
    [Abstract] [Full Text] [Related]

  • 15. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
    Brambilla C, Escobedo A, Artioli R, Lechuga MJ, Motta M.
    Anticancer Drugs; 1992 Feb 15; 3(1):3-8. PubMed ID: 1535804
    [Abstract] [Full Text] [Related]

  • 16. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
    Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L.
    J Natl Cancer Inst; 2000 Jun 07; 92(11):903-11. PubMed ID: 10841825
    [Abstract] [Full Text] [Related]

  • 17. Buserelin in the treatment of prostatic cancer.
    Roila F.
    Biomed Pharmacother; 1989 Jun 07; 43(4):279-85. PubMed ID: 2506941
    [Abstract] [Full Text] [Related]

  • 18. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O'Donoghue EP, Sikora K.
    Am J Clin Oncol; 1988 Jun 07; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [Abstract] [Full Text] [Related]

  • 19. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, de Jong FH, Klijn JG, Matroos AW, de Voogt HJ.
    J Urol; 1987 May 07; 137(5):912-8. PubMed ID: 2952810
    [Abstract] [Full Text] [Related]

  • 20. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
    Bianco AR, Rosso R, Calabresi F, Fiorentino M, Lopez M, Sismondi PG, Lenti R, Fosser V, De Placido S, Perrone F.
    Eur J Gynaecol Oncol; 1991 May 07; 12(6):429-37. PubMed ID: 1839730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.